Univariable survival analyses for stages I–IV showed that loss of CDX2 was significantly associated with a shorter 5‐year OS (log‐rank P = 0.016, n = 1045; Fig. S2A and Table 1), and multivariable analyses showed that CDX2 had prognostic value independent of relevant prognostic factors, including histopathological grade, tumor location, MSI, and BRAF mutation (HR 1.53; 95% CI 1.07–2.18; P = 0.021; Table 1 (upper panel)). Here, BRAF is linked to neoplasm.